Scholarlink

<p>Psoriatic arthritis (PsA) is a&#xa0;chronic inflammatory disease that is often associated with psoriasis of the skin. Typical symptoms include arthritis, enthesitis, dactylitis and changes to the skin and nails. Associated conditions such as chronic inflammatory bowel disease, uveitis and cardiometabolic comorbidities are also common. Genetic factors and dysregulation of the interleukin (IL)-23/IL-17 axis play a&#xa0;central role in the disease’s pathophysiology. Due to the diversity of symptoms, diagnosis can be difficult; however, CASPAR criteria and imaging techniques can help. Treatment decisions are based on disease severity and affected manifestations. Not all patients require disease-modifying therapy (DMARDs) from the outset. In mild cases, symptomatic treatment, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or local measures, may be sufficient. However, if inflammation persists or joint damage is imminent, DMARD therapy should be initiated at an early stage. A&#xa0;manifestation-related, individualised, interdisciplinary approach to treatment is crucial for managing inflammation while maintaining function and quality of life in the long term.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Müssen Patienten mit einer Psoriasis-Arthritis mit DMARDs behandelt werden?

  • 期刊论文

  • 发表日期：

    2026年3月12日

查看全文
  • Michaela Köhm

摘要

Psoriatic arthritis (PsA) is a chronic inflammatory disease that is often associated with psoriasis of the skin. Typical symptoms include arthritis, enthesitis, dactylitis and changes to the skin and nails. Associated conditions such as chronic inflammatory bowel disease, uveitis and cardiometabolic comorbidities are also common. Genetic factors and dysregulation of the interleukin (IL)-23/IL-17 axis play a central role in the disease’s pathophysiology. Due to the diversity of symptoms, diagnosis can be difficult; however, CASPAR criteria and imaging techniques can help. Treatment decisions are based on disease severity and affected manifestations. Not all patients require disease-modifying therapy (DMARDs) from the outset. In mild cases, symptomatic treatment, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or local measures, may be sufficient. However, if inflammation persists or joint damage is imminent, DMARD therapy should be initiated at an early stage. A manifestation-related, individualised, interdisciplinary approach to treatment is crucial for managing inflammation while maintaining function and quality of life in the long term.